Catalog No.
VVV25903
Species reactivity
Poliovirus type 1 (strain Sabin), Poliovirus type 1 (strain Mahoney), Poliovirus type 2 (strain Lansing), Poliovirus type 3 (strains P3/Leon/37 and P3/Leon 12A[1]B)
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Target
Genome polyprotein, P1, Capsid protein VP0, VP4-VP2, Capsid protein VP4, P1A, Virion protein 4, Capsid protein VP2, P1B, Virion protein 2, Capsid protein VP3, P1C, Virion protein 3, Capsid protein VP1, P1D, Virion protein 1, P2, Protease 2A (P2A), Picornain 2A, Protein 2A, Protein 2B (P2B), Protein 2C (P2C), P3, Protein 3AB, Protein 3A (P3A), Viral protein genome-linked (VPg), Protein 3B (P3B), Protein 3CD, Protease 3C, Picornain 3C, RNA-directed RNA polymerase (RdRp), 3D polymerase (3Dpol), Protein 3D (3D)
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03301, P03300, Q8B3S1, P03302, P06210
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
FS0291
Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines., PMID:39827284
Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient., PMID:39599874
Enterovirus Antibodies: Friends and Foes., PMID:39505825
A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes., PMID:37816742
Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly., PMID:36507670
Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease., PMID:35091341
A defective viral genome strategy elicits broad protective immunity against respiratory viruses., PMID:34852237
Rhinovirus Inhibitors: Including a New Target, the Viral RNA., PMID:34578365
Interaction of Poliovirus Capsid Proteins with the Cellular Autophagy Pathway., PMID:34452452
Expression of immunogenic poliovirus Sabin type 1 VP proteins in transgenic tobacco., PMID:32659239
Phylogenetic characteristics and molecular epidemiological analysis of novel enterovirus EV-B83 isolated from Tibet, China., PMID:32313119
Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients., PMID:32089462
Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape., PMID:31953427
Evolutionary and Structural Overview of Human Picornavirus Capsid Antibody Evasion., PMID:31482072
Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test., PMID:31427704
Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes., PMID:30575284
A simple and safe antibody neutralization assay based on polio pseudoviruses., PMID:30273512
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis., PMID:29925653
Non-neutralizing Antibody Responses against VP1 in Enterovirus A, B, C and Rhinovirus A species among Infants and Children in Shanghai., PMID:29615683
Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak., PMID:29444940
Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo., PMID:29337652
A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses., PMID:29311608
Exploitation of stable nanostructures based on the mouse polyomavirus for development of a recombinant vaccine against porcine circovirus 2., PMID:28922413
Single amino acid fingerprinting of the human antibody repertoire with high density peptide arrays., PMID:28167275
Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines., PMID:28103317
Cryo-electron Microscopy Structures of Expanded Poliovirus with VHHs Sample the Conformational Repertoire of the Expanded State., PMID:27852863
[Immunoreactivity of chimeric proteins carrying poliovirus epitopes on the VP6 of rotavirus as a vector]., PMID:27830685
Expression and purification of polioviral proteins in E. coli, and production of antisera as reagents for immunological assays., PMID:27565898
Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine., PMID:27032093
Molecular and Phenotypic Characterization of a Highly Evolved Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014., PMID:27019095
Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site., PMID:26764003
Trypsin diminishes the rat potency of polio serotype 3., PMID:26321654
Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs)., PMID:26014941
Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1., PMID:25879139
Lower anti-echovirus antibody responses in children presenting to hospital with asthma exacerbations., PMID:25640320
Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication., PMID:25600519
Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013., PMID:25550350
Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections., PMID:25263613
Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010., PMID:25136105
Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity., PMID:24501405
Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination., PMID:24459191
Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention., PMID:23935826
VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population., PMID:23863902
Conformational shift of a major poliovirus antigen confirmed by immuno-cryogenic electron microscopy., PMID:23772035
Serological cross-reactivity between human polyomaviruses., PMID:23650080
Structure of the Fab-labeled "breathing" state of native poliovirus., PMID:22398295
Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073., PMID:22024515
An externalized polypeptide partitions between two distinct sites on genome-released poliovirus particles., PMID:21775460
[Expression of VP0 protein of enterovirus 71 in Escherichia coli and generation of the corresponding polyclonal antibodies in guinea pigs]., PMID:21557912
Identification and characterization of a cross-neutralization epitope of Enterovirus 71., PMID:21501643
For research use only. Not for human or drug use.
